Citation: | SUN Jianhua, JI Zhonghe, YU Yang, WU Haitao, LI Yan. Clinical Investigation on Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy on Patients with Peritoneal Carcinomatosis from Epithelial Ovarian Cancer[J]. Cancer Research on Prevention and Treatment, 2016, 43(4): 282-286. DOI: 10.3971/j.issn.1000-8578.2016.04.009 |
[1] |
Hennessy BT, Coleman RL, Markman M. Ovarian cancer[J]. Lancet, 2009, 374(9698): 1371-82.
|
[2] |
McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage Ⅲ and stage Ⅳ ovarian cancer[J]. N Engl J Med, 1996, 33 4(1): 1-6.
|
[3] |
Ozols RF, Bundy BN, Greer BE, et al. Phase Ⅲ trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage Ⅲ ovarian cancer: a Gynecologic Oncology Group study[J]. J Clin Oncol, 2003, 21 (17): 3194-200.
|
[4] |
Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis[J]. J Clin Oncol, 2002, 20 (5): 1248-59.
|
[5] |
van Driel WJ, Lok CA, Verwaal V, et al. The role of hyperthermic intraperitoneal intraoperative chemotherapy in ovarian cancer[J]. Curr Treat Options Oncol, 2015, 16(4): 14.
|
[6] |
Yonemura Y, Canbay E, Endou Y, et al. Peritoneal cancer treatment[J]. Expert Opin Pharmacother, 2014, 15(5): 623-36.
|
[7] |
Maggiori L, Elias D. Curative treatment of colorectal peritoneal carcinomatosis: current status and future trends[J]. Eur J Surg Oncol, 2010, 36(7): 599-603.
|
[8] |
Sugarbaker PH. Five reasons why cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy must be regarded as the new standard of care for diffuse malignant peritoneal mesotheliomia[J]. Ann Surg Oncol, 2010, 17(6): 1710-2.
|
[9] |
Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy[J]. J Clin Oncol, 20 12, 30(20): 2449-56.
|
[10] |
Huang CQ, Yang XJ, Yu Y, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for patients with peritoneal carcinomatosis from colorectal cancer: A phase Ⅱ study from a Chinese center[J]. PLoS One, 2014, 9(9): e108509.
|
[11] |
Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase Ⅲ randomized clinical trial[J]. Ann Surg Oncol, 20 11, 18(6): 1575-81.
|
[12] |
Li Y, Zhou YF, Liang H, et al. Expert consensus on the cytoreductive surgery and hyperthermic intraperitoneal chemotherapy to treat peritoneal carcinomatosis[J]. Zhongguo Zhong Liu Lin Chuang, 2015, 42(4): 198-206. [李雁, 周云峰, 梁 寒, 等. 细胞减灭术加腹腔热灌注化疗治疗腹膜表面肿瘤的专 家共识[J]. 中国肿瘤临床, 2015, 42(4): 198-206.]
|
[13] |
Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer[J]. Cancer Chemother Pharmacol, 19 99, 43 Suppl: S15-25.
|
[14] |
Sugarbaker PH. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome[J]. Eur J Surg Oncol, 2001, 27 (3): 239-43.
|
[15] |
Bukowski RM, Ozols RF, Markman M. The management of recurrent ovarian cancer[J]. Semin Oncol, 2007, 34(2 Suppl 2): S1-15.
|
[16] |
Roviello F, Pinto E, Corso G, et al. Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer[J]. J Surg Oncol, 2010, 102(6): 663-70.
|
[17] |
Ansaloni L, Agnoletti V, Amadori A, et al. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer[J]. Int J Gynecol Cancer, 2012, 22(5): 778-85.
|
[18] |
Ceelen WP, Van Nieuwenhove Y, Van Belle S, et al. Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer[J]. Ann Surg Oncol, 20 12, 19(7): 2352-9.
|
[19] |
Spiliotis J, Halkia E, Lianos E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: A prospective randomized phase III study[J]. Ann Surg Oncol, 2015, 22(5): 15 70-5.
|
[20] |
Chua TC, Robertson G, Liauw W, et al. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results[J]. J Cancer Res Clin Oncol, 2009, 13 5(12): 1637-45.
|
[21] |
Cascales Campos P, Gil J, Parrilla P. Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary and recurrent advanced ovarian cancer[J]. Eur J Surg Oncol, 2014, 40 (8): 970-5.
|
[22] |
Bakrin N, Bereder JM, Decullier E, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients[J]. Eur J Surg Oncol, 2013, 39(12): 14 35-43.
|
[23] |
Bakrin N, Cotte E, Golfier F, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients[J]. Ann Surg Oncol, 2012, 19 (13): 4052-8.
|
[1] | CAO Wenjing, WANG Yulin, ZHAI Yuqing, ZHANG Zongliang, YUAN Jiangshui, SONG Weiqing. Expression and Clinical Significance of MIS18BP1 in Bladder Cancer Tissues[J]. Cancer Research on Prevention and Treatment, 2024, 51(3): 163-168. DOI: 10.3971/j.issn.1000-8578.2024.23.1041 |
[2] | ZHANG Yuanyuan, FANG Zhaoqin, LIANG Chao. Screening of Genes Involved in Hepatoma Cells SMMC-7721 Stress Response Induced by Different Stressors[J]. Cancer Research on Prevention and Treatment, 2016, 43(6): 463-467. DOI: 10.3971/j.issn.1000-8578.2016.06.006 |
[3] | Pei Feng, Zhu Yi. Clinical Significance of Cytokeratin18 Fragments in Diagnosis of Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2012, 39(04): 439-441. DOI: 10.3971/j.issn.1000-8578.2012.04.018 |
[4] | YANG Guang-min, LI Shou-qing, MA Yin-fu, WEI Bing-bing, SHI Yang, TAN Yan. Anti-tumor Immunotherapy Effect of Co-expression Genetic Vaccine MAGE-1/IL-18[J]. Cancer Research on Prevention and Treatment, 2010, 37(03): 294-297. DOI: 10.3971/j.issn.1000-8578.2010.03.014 |
[5] | YANG Sheng, LU Hui-shan, CHEN Xiang-qi, LIN Ting-yan, LI Zhi-ying, KANG Ming-qiang. Effect of IL-18 on Growth and Apoptosis of Lewis Lung Cancer Xenografts in C57BL/6 Mice[J]. Cancer Research on Prevention and Treatment, 2009, 36(07): 563-565. DOI: 10.3971/j.issn.1000-8578.2009.07.007 |
[6] | ZHAO Hong-xia, WANG Yan-kui, LUO Bing, YIN Guang-jie. Influence of HPV18E6 Small Interfering RNA on p21,VEGF,Bax and Bcl-2 Genes in HeLa Cells[J]. Cancer Research on Prevention and Treatment, 2009, 36(04): 261-264. DOI: 10.3971/j.issn.1000-8578.2009.04.001 |
[7] | YANG Qin, CHEN Hong-lei, LIU Ming-qiu, FANG Zhong. PCR-SSCP Analysis of FADD Gene Mutation in Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2006, 33(03): 162-164. DOI: 10.3971/j.issn.1000-8578.442 |
[8] | GAO Yan-e, YANG Hui-ping, ZHANG Ju, GUO Jin-zhu, LIU Ning-xia, YAN Xiao-jun. Cloning and Sequencing of Human Papillomavirus Type 18 L1 Gene from Cervical Cancer Tissue[J]. Cancer Research on Prevention and Treatment, 2006, 33(03): 159-161. DOI: 10.3971/j.issn.1000-8578.441 |
[9] | LI Ji-mei, LI Chun-hai, WANG Qin-qin, et al, . Detect ion of MUC1 and GST-P Gene by means of RT-PCR in Axillary Lymph Nodes Taken from Breast Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2001, 28(05): 351-353. DOI: 10.3971/j.issn.1000-8578.1357 |
[10] | Luo YuanHui, . The Point Mutation of Ras and p53 Genes in Paraffin-embedded Gastric Cancer Tissues by PCR-RFLP Analysis[J]. Cancer Research on Prevention and Treatment, 1995, 22(2): 68-71. |